MX2017004300A - ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE A4ß7 NOVEDOSOS. - Google Patents
ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE A4ß7 NOVEDOSOS.Info
- Publication number
- MX2017004300A MX2017004300A MX2017004300A MX2017004300A MX2017004300A MX 2017004300 A MX2017004300 A MX 2017004300A MX 2017004300 A MX2017004300 A MX 2017004300A MX 2017004300 A MX2017004300 A MX 2017004300A MX 2017004300 A MX2017004300 A MX 2017004300A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide monomer
- novel
- response
- art
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La invención se refiere a compuestos de diméricos de peptídicos y compuestos monoméricos peptídicos que inhiben eficazmente la unión de u4137 a la molécula de adhesión celular a adresina mucosal (MAdCAM) in vivo, poseen selectividad elevada contra la unión de ct431 y tienen estabilidad elevada en condiciones gastrointestinales; la presente invención se ha desarrollado en respuesta al presente estado de la técnica, y en particular, en respuesta a los problemas y necesidades en la técnica que aún no han sido completamente resueltos por antagonistas de integrina actualmente disponibles.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462058506P | 2014-10-01 | 2014-10-01 | |
US201462058510P | 2014-10-01 | 2014-10-01 | |
US201562149257P | 2015-04-17 | 2015-04-17 | |
US201562192934P | 2015-07-15 | 2015-07-15 | |
PCT/US2015/053558 WO2016054411A1 (en) | 2014-10-01 | 2015-10-01 | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004300A true MX2017004300A (es) | 2017-12-18 |
Family
ID=55631539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004300A MX2017004300A (es) | 2014-10-01 | 2015-10-01 | ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE A4ß7 NOVEDOSOS. |
Country Status (13)
Country | Link |
---|---|
US (5) | US9809623B2 (es) |
EP (1) | EP3200812B8 (es) |
JP (1) | JP2017535527A (es) |
KR (1) | KR20170108936A (es) |
CN (1) | CN106999537B (es) |
AU (1) | AU2015328002A1 (es) |
BR (1) | BR112017006826A2 (es) |
CA (1) | CA2962642A1 (es) |
IL (1) | IL251260A0 (es) |
MX (1) | MX2017004300A (es) |
RU (1) | RU2017114414A (es) |
SG (1) | SG11201702553RA (es) |
WO (1) | WO2016054411A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
RS62392B1 (sr) | 2014-05-16 | 2021-10-29 | Protagonist Therapeutics Inc | Tioetar peptidni antagonisti alfa4beta7 integrina |
SG11201700327WA (en) | 2014-07-17 | 2017-02-27 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017079821A1 (en) | 2015-11-11 | 2017-05-18 | Encycle Therapeutics, Inc. | Fragment synthesis of cyclic peptides |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
US20190247457A1 (en) * | 2016-06-16 | 2019-08-15 | The University Of Tokyo | Plexin Binding Regulator |
JP7035044B2 (ja) | 2016-11-11 | 2022-03-14 | ジーランド ファーマ エー/エス | α4β7インテグリンを標的とする環状ペプチド多量体 |
IL270465B (en) | 2017-05-10 | 2022-09-01 | Encycle Therapeutics Inc | Cyclic peptides targeting alpha4beta7 integrin |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
AU2021205415A1 (en) * | 2020-01-10 | 2022-07-21 | Protagonist Therapeutics, Inc. | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists |
BR112022013957A2 (pt) | 2020-01-15 | 2022-10-11 | Janssen Biotech Inc | Inibidores peptídicos do receptor de interleucina-23 e uso dos mesmos para tratar doenças inflamatórias |
US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ.ベー. | インターロイキン-23受容体のペプチド阻害剤の組成物 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
DE69226077T2 (de) | 1991-04-05 | 1998-12-03 | Genentech Inc | PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa |
AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
WO1999002194A1 (en) | 1997-07-11 | 1999-01-21 | Innerdyne, Inc. | Methods and systems for preparing and sealing radiation delivery structures |
US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
WO1999026615A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
WO2000006243A2 (en) | 1998-07-28 | 2000-02-10 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
WO2000061580A1 (en) | 1999-04-12 | 2000-10-19 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compounds as integrin antagonists |
WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
CZ20031927A3 (cs) | 2001-01-09 | 2003-10-15 | Merck Patent Gmbh | Farmaceutický prostředek na bázi inhibitorů receptoru tyrosinkinázy a inhibitorů angiogeneze |
DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
AU2003254585A1 (en) | 2002-07-24 | 2004-02-16 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
WO2004058307A1 (en) | 2002-12-18 | 2004-07-15 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
US20070166711A1 (en) | 2003-04-15 | 2007-07-19 | Samuels Mark E | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
PL2332968T3 (pl) | 2003-11-05 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Stabilizowane alfa-helikalne peptydy i ich zastosowania |
WO2005064345A2 (en) | 2003-12-19 | 2005-07-14 | Applera Corporation | Methods and systems for protein and peptide evidence assembly |
JP4315982B2 (ja) | 2004-01-09 | 2009-08-19 | ファイザー インコーポレイティッド | MAdCAMに対する抗体 |
US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
CA2578592A1 (en) | 2004-06-24 | 2006-01-05 | The Walter And Eliza Hall Institute Of Medical Research | Conjugates and therapeutic uses thereof |
CA2581319A1 (en) | 2004-09-23 | 2006-03-30 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
JP2008521840A (ja) | 2004-11-30 | 2008-06-26 | ガストロテック・ファルマ・アクティーゼルスカブ | 成長ホルモン分泌促進物質レセプター1aリガンド |
US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
EP2371957A1 (en) | 2006-04-12 | 2011-10-05 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
MX2009008104A (es) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
ES2465223T3 (es) | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
WO2008144041A1 (en) | 2007-05-21 | 2008-11-27 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
US20090131317A1 (en) | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
EP2288621A4 (en) | 2007-07-06 | 2012-01-04 | Valorisation Hsj Soc En Commandite | IL23 RECEPTOR ANTAGONISTS AND THEIR USE |
CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
BRPI0922708A2 (pt) | 2008-12-05 | 2018-11-06 | Univ California | peptídeos mini-hepcidina e métodos de uso do mesmo |
DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
CA2758264A1 (en) | 2009-04-08 | 2010-10-14 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素(hepcidin)結合之核酸類 |
CN102834408A (zh) | 2010-01-25 | 2012-12-19 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
WO2011149942A2 (en) | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
EP3626253B8 (en) | 2010-08-11 | 2022-04-20 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
EP2668199B1 (en) | 2011-01-27 | 2017-09-06 | Ramot at Tel Aviv University, Ltd. | Glycogen synthase kinase-3 inhibitors |
US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
AU2012271691A1 (en) | 2011-06-14 | 2014-01-16 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
JP6571333B2 (ja) | 2011-12-09 | 2019-09-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改変ミニヘプシジンペプチドおよびその使用方法 |
US20150157692A1 (en) | 2012-05-23 | 2015-06-11 | The University Of Chicago | Methods of treating obesity |
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
CN105378159A (zh) | 2013-02-15 | 2016-03-02 | Srx心脏有限责任公司 | 调节血清低密度脂蛋白(LDL)水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型(PCSK9)变构结合配体 |
SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
US9221872B2 (en) | 2013-06-24 | 2015-12-29 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
US10293020B2 (en) | 2013-06-27 | 2019-05-21 | Stealth Biotherapeutics Corp. | Peptide therapeutics and methods for using same |
CA2926685A1 (en) | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
WO2015112700A1 (en) | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
CA2948283A1 (en) | 2014-04-07 | 2015-10-15 | Merganser Biotech, Inc. | Hepcidin mimetic peptides and uses thereof |
RS62392B1 (sr) | 2014-05-16 | 2021-10-29 | Protagonist Therapeutics Inc | Tioetar peptidni antagonisti alfa4beta7 integrina |
WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
CN107075574A (zh) | 2014-06-27 | 2017-08-18 | 领导医疗有限公司 | 铁调素和微型铁调素类似物及其用途 |
WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
SG11201700327WA (en) | 2014-07-17 | 2017-02-27 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
WO2016054445A1 (en) * | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
EP3240799B1 (en) | 2014-12-29 | 2021-03-31 | The Regents of the University of California | S-alkylated hepcidin peptides and methods of making and using thereof |
US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
US20170369871A1 (en) | 2015-01-12 | 2017-12-28 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
JP6858174B2 (ja) | 2015-07-15 | 2021-04-14 | プロタゴニスト セラピューティクス, インコーポレイテッド | インターロイキン23受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用 |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
CA3049889A1 (en) | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
WO2020014646A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2021007433A1 (en) | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
-
2015
- 2015-10-01 AU AU2015328002A patent/AU2015328002A1/en not_active Abandoned
- 2015-10-01 SG SG11201702553RA patent/SG11201702553RA/en unknown
- 2015-10-01 WO PCT/US2015/053558 patent/WO2016054411A1/en active Application Filing
- 2015-10-01 CA CA2962642A patent/CA2962642A1/en active Pending
- 2015-10-01 KR KR1020177011880A patent/KR20170108936A/ko unknown
- 2015-10-01 US US14/872,975 patent/US9809623B2/en active Active
- 2015-10-01 RU RU2017114414A patent/RU2017114414A/ru not_active Application Discontinuation
- 2015-10-01 MX MX2017004300A patent/MX2017004300A/es unknown
- 2015-10-01 JP JP2017517669A patent/JP2017535527A/ja active Pending
- 2015-10-01 BR BR112017006826A patent/BR112017006826A2/pt not_active Application Discontinuation
- 2015-10-01 EP EP15846131.9A patent/EP3200812B8/en active Active
- 2015-10-01 CN CN201580064273.5A patent/CN106999537B/zh active Active
-
2016
- 2016-02-17 US US15/046,325 patent/US9518091B2/en active Active
-
2017
- 2017-03-19 IL IL251260A patent/IL251260A0/en unknown
- 2017-09-07 US US15/698,407 patent/US20180148477A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/781,516 patent/US11111272B2/en active Active
-
2021
- 2021-07-16 US US17/378,328 patent/US20220162261A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2015328002A1 (en) | 2017-04-27 |
EP3200812A4 (en) | 2018-02-28 |
WO2016054411A1 (en) | 2016-04-07 |
BR112017006826A2 (pt) | 2017-12-12 |
KR20170108936A (ko) | 2017-09-27 |
US11111272B2 (en) | 2021-09-07 |
RU2017114414A3 (es) | 2019-04-29 |
JP2017535527A (ja) | 2017-11-30 |
EP3200812A1 (en) | 2017-08-09 |
US9809623B2 (en) | 2017-11-07 |
US9518091B2 (en) | 2016-12-13 |
US20200308229A1 (en) | 2020-10-01 |
SG11201702553RA (en) | 2017-04-27 |
US20160152664A1 (en) | 2016-06-02 |
US20180148477A1 (en) | 2018-05-31 |
EP3200812B1 (en) | 2020-11-25 |
US20220162261A1 (en) | 2022-05-26 |
CA2962642A1 (en) | 2016-04-07 |
CN106999537B (zh) | 2020-01-31 |
EP3200812B8 (en) | 2021-04-28 |
RU2017114414A (ru) | 2018-11-06 |
CN106999537A (zh) | 2017-08-01 |
IL251260A0 (en) | 2017-05-29 |
US20160159862A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017004300A (es) | ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE A4ß7 NOVEDOSOS. | |
EP3960754A3 (en) | Alpha4beta7 integrin thioether peptide antagonists | |
PH12016501763A1 (en) | Multispecific antibodies | |
NZ706909A (en) | Novel α4ß7 peptide dimer antagonists | |
TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
EA202092435A3 (ru) | Моноклональные антитела против bcma | |
MY190145A (en) | Isocyanate-free reactive polyurethane compositions | |
EA201890058A1 (ru) | Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного | |
MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
NZ725568A (en) | Modified j-chain | |
PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
WO2016166296A3 (en) | Humanized anti-axl antibodies | |
TR201910057T4 (tr) | Kauçuk bi̇leşi̇mleri̇ | |
EP3302468A4 (en) | SMALL MOLECULE ANALOGUES OF THE NEMO BINDING PEPTIDE | |
WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
WO2016092561A3 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
EA201890177A1 (ru) | Мультиспецифические связывающие белки | |
WO2016024289A3 (en) | Novel salts of nilotinib and polymorphs thereof |